In the ARCHER 1050 study, another second-generation EGFR-TKI, dacomitinib, provided PFS and OS benefits over gefitinib in the first-line treatment of NSCLC patients with EGFR mutations [32]. Here, EGFR is linked to non-small cell lung carcinoma.